Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus

Emily C. Somers, Wendy Marder, Gregory M. Christman, Vladimir Ognenovski, V. Ognenovski, W. Joseph McCune
Arthritis and rheumatism · 2005 · vol. 52(9) , pp. 2761–2767 · doi:10.1002/art.21263 · PMID:16142702 · W2019229100
Non-randomised trial OA: bronze CC0 ⤵ 6 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study found that gonadotropin-releasing hormone analog treatment during cyclophosphamide therapy significantly reduced premature ovarian failure in women with severe lupus.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Cyclophosphamide (CYC) therapy for systemic lupus erythematosus (SLE), a disease predominantly affecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ovarian failure (POF). This study was performed to evaluate the effectiveness of depot leuprolide acetate, a synthetic gonadotropin-releasing hormone analog (GnRH-a), for protection against POF during CYC therapy. METHODS: Young women with severe SLE treated in a standardized protocol of monthly intravenous bolus CYC were offered treatment with GnRH-a (depot leuprolide acetate; a 3.75-mg monthly injection during the standard CYC regimen). Patients treated with GnRH-a were compared with controls individually matched by age (+/-5 years) and by cumulative CYC dose (+/-5 gm). Reproductive status was determined after a minimum followup of 3 years after CYC therapy. The primary outcome was time to POF. Paired summary statistical analyses, Kaplan-Meier survival estimates, and Cox regression analyses were performed to assess differences in outcome between groups. RESULTS: POF developed in 1 of 20 women treated with GnRH-a (5%) compared with 6 of 20 controls (30%) matched by age and cumulative CYC dose (matched odds ratio 0.09, P < 0.05). Kaplan-Meier estimates demonstrated improved cumulative ovarian protection over time in the GnRH-a-treated group (P = 0.04). CONCLUSION: Treatment with GnRH-a during CYC therapy was associated with a significant reduction of POF in young women with severe SLE.

My notes (saved in your browser only)

MeSH descriptors

Cyclophosphamide Fertility Agents, Female Immunosuppressive Agents Leuprolide Lupus Erythematosus, Systemic Primary Ovarian Insufficiency Adult Cyclophosphamide Data Interpretation, Statistical Female Fertility Agents, Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Immunosuppressive Agents Leuprolide Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic Ovary

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (47)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-14T06:09:40.812857+00:00
pubmed
last seen: 2026-10-08T21:03:18.265172+00:00
License: CC0 · commercial use OK